Aspyrian Therapeutics Financing
Aspyrian Therapeutics, Inc., Corporation just submitted form D about $56.05 million equity financing. The date of first sale was 2016-02-24. Aspyrian Therapeutics was able to fundraise $55.20 million. That is 98.48% of the round of financing. The total financing amount was $56.05 million. The financing document was filed on 2016-10-05. The reason for the financing was: unspecified. The fundraising still has about $850,001 more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Aspyrian Therapeutics is based in California. The firm’s business is Biotechnology. The D form was filed by Miguel Garcia-Guzman Chief Executive Officer. The company was incorporated more than five years ago. The filler’s address is: 10581 Roselle Street, Suite 115, San Diego, Ca, California, 92121. Miguel Garcia-Guzman is the related person in the form and it has address: 10581 Roselle Street, Suite 115, San Diego, Ca, California, 92121. Link to Aspyrian Therapeutics Filing: 000159521516000004.
Analysis of Aspyrian Therapeutics Offering
On average, companies in the Biotechnology sector, sell 73.77% of the total offering size. Aspyrian Therapeutics sold 98.48% of the offering. The fundraising is still open. Could this mean that the trust in Aspyrian Therapeutics is high? The average investment size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 1,692.21% bigger than the average for companies in the Biotechnology sector. The minimum investment for this financing was set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Aspyrian Therapeutics Also
The Form D signed by Miguel Garcia-Guzman might help Aspyrian Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.